JAK2 and essential thrombocythemia: In addition to the high rates of CHR, symptomatic improvement and improvement in or resolution of need for therapeutic phlebotomy, many patients with PV and ET may experience a sustained decrease in JAK2-V617F allelic burden with a potential for disease modification due to malignant clone targeting by interferon [21].